Evotec (ETR:EVT) Shares Down 0.2% – Here’s What Happened

Evotec SE (ETR:EVT)’s stock price fell 0.2% on Thursday. The stock traded as low as €2.78 and last traded at €2.80. 792,348 shares changed hands during trading, a decline of 42% from the average daily volume of 1,360,000 shares. The stock had previously closed at €2.81.

Evotec Trading Down 0.2%

The stock has a market capitalization of $519.53 million, a price-to-earnings ratio of -3.03, a P/E/G ratio of 0.98 and a beta of 1.26. The company has a debt-to-equity ratio of 71.50, a quick ratio of 2.97 and a current ratio of 2.33. The firm has a fifty day moving average of €3.30 and a 200-day moving average of €4.30.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.